Journal
FUTURE MEDICINAL CHEMISTRY
Volume 3, Issue 13, Pages 1585-1605Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.11.106
Keywords
-
Categories
Ask authors/readers for more resources
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the world today. Bronchodilators, particularly muscarinic antagonists and beta 2 agonists, are recommended for patients with moderate to severe COPD. Dual-pharmacology muscarinic antagonist-beta(2) agonist (MABA) molecules present an exciting new approach to the treatment of COPD by combining muscarinic antagonism and beta(2) agonism in a single entity. They have the potential to demonstrate additive or synergistic bronchodilation over either pharmacology alone. Due to this enticing prospect, several companies have now reported MABA discovery efforts through a conjugated/linked strategy with one candidate (GSK-961081) demonstrating clinical proof of concept. Several MABA crystal forms have been identified, satisfying the requirements for inhaled dosing devices. There are significant challenges in designing MABAs, but the potential to achieve enhanced bronchoprotection in patients and facilitate 'triple therapy' makes this an extremely important and exciting area of pharmaceutical research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available